How to Steer Clear of a Social Security Iceberg
Your editorial 'The Social Security Iceberg Gets Closer' (June 20) rightly warns of the urgent need to address Social Security's looming insolvency. Doing nothing isn't an answer, yet Congress has become paralyzed by a false choice between raising taxes and cutting benefits.
There's another path, which a group of bipartisan senators and I have outlined in what we call the 'Big Idea,' a practical update to how Social Security is financed. The reform can save the program not merely for today's seniors but also for our children and grandchildren.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Early data suggest Roche's NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia A1 The NXT007 clinical development programme aims to normalise haemostasis and minimise treatment burden2,3 Three phase III clinical studies on NXT007, a next-generation bispecific antibody, set to begin in 20261 Basel, 23 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a next-generation investigational bispecific antibody, engineered by Chugai, a member of the Roche Group. Early data from the NXTAGE study suggest that NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A (without factor VIII inhibitors). NXT007 showed a tolerable safety profile with no thromboembolic events reported so far.1 These results were featured as an oral presentation at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress, 21-25 June, Washington D.C., United States.1 'These NXT007 data are promising for people with haemophilia A and underscore our ongoing commitment to advancing care and addressing the real-world challenges faced by this community,' said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. 'Hemlibra established a new standard of care, and our focus is to continue to deliver breakthrough innovation that might ultimately help people with haemophilia to live their lives in a manner unaffected by this condition.' NXT007 leverages the Roche Group's expertise in haemophilia A and bispecific antibody development. Our goal is to bring a next generation prophylactic to our portfolio, offering greater therapeutic choice, sustained, elevated bleed protection and reduced treatment burden with factor independence - to allow patients to experience freedom from constant vigilance and have confidence in bleed protection. NXT007 will be further evaluated in a robust clinical development programme, including ongoing phase I/II clinical trials, with additional phase II data expected later this year. There are also three phase III studies currently planned for 2026, including a phase III head-to-head study with Roche's Hemlibra, the first available prophylactic treatment that can be administered subcutaneously and with flexible dosing options (every week, two weeks or four weeks).4,5 Part B of the phase I/II NXTAGE study, conducted by Chugai, in Japan, Taiwan and South Korea, is evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of prophylaxis with NXT007 in people with haemophilia A without factor VIII inhibitors who had not been previously treated with Hemlibra® (emicizumab).1 Thirty participants (from 12 to 65 years of age) were enrolled in four cohorts (B-1 to B-4) to receive ascending doses of subcutaneous NXT007 every two-to-four weeks during the maintenance period (following four-to-six weeks of loading doses). In presented data from the primary analysis, no treated bleeds were observed with NXT007 in the highest dose cohorts (B-3 and B-4). NXT007 was well tolerated, with no thromboembolic events observed so far.1 About NXT007NXT007 is a next-generation investigational bispecific antibody, being investigated as a prophylactic (preventive) treatment option for people with haemophilia A.1,2,3 NXT007 was engineered by Chugai – a member of the Roche Group – built on Hemlibra® (emicizumab)'s framework, with the aim of optimising factor VIII-mimetic activity and half-life, to further enhance potency, efficacy, dosing and administration convenience. NXT007 brings together factor IXa and factor X, proteins required to activate the natural coagulation cascade.1,2,3 NXT007 is being studied in a robust clinical development programme exploring its potential to achieve sustained elevated bleed protection equivalent to people who do not have haemophilia A (sustained haemostatic normalisation), and reduced treatment burden with factor independence, offering people living with haemophilia A greater therapeutic choice.1,2,3 About haemophilia AHaemophilia A is an inherited, serious disorder in which a person's blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. Haemophilia A affects around 900,000 people worldwide.6,7 People with haemophilia A either lack or do not have enough of a clotting protein called factor VIII. In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa- and X, which is a critical step in the formation of a blood clot to help stop bleeding. Depending on the severity of their symptoms, people with haemophilia A can bleed frequently, especially into their joints or muscles.8 These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility and long-term joint damage.9 A serious complication of treatment is the development of inhibitors to factor VIII replacement therapies. Inhibitors are antibodies developed by the body's immune system that bind to and block the efficacy of replacement factor VIII, making it difficult, if not impossible, to obtain a level of factor VIII sufficient to control bleeding.6 About Roche in haematologyRoche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3 and Tecentriq® (atezolizumab). Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. References[1] 1. Shima M, et al. NXT007 Prophylaxis in Emicizumab-Naive Persons with Hemophilia A without Inhibitor: Phase I/II Study (NXTAGE) Presented at International Society on Thrombosis and Haemostasis (ISTH) congress; 2025 June. Abstract OC.20.3.[2] Shima M, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Injection of NXT007, an Emicizumab-Based Next-Generation Bispecific Antibody, in Healthy Volunteers (NXTAGE Study). Presented at: International Society on Thrombosis and Haemostasis (ISTH) Congress; 2023 July 28. Abstract OC 69.4. [3] Teranishi-Ikawa Y., et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state. Journal of Thrombosis and Haemostasis. 2023; doi: 10.1016/ Hemlibra SmPC [Internet; cited 2025 June] Available from: [5] FDA Prescribing Information [Internet; cited 2025 June]. Available from: [6] Srivastava A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26 (Suppl 6): 1-158.[7] Iorio A, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. Ann Intern Med. 2019;171(8):540-546.[8] NHS. Symptoms of haemophilia [Internet; cited 2025 June]. Available from: [9] Franchini M, et al. Haemophilia A in the third millennium. Blood Rev. 2013; 179-84. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Nina MählitzPhone: +41 79 327 54 74 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment Media Investor Release phase I_II data on NXT007 EnglishError al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Bloomberg
an hour ago
- Bloomberg
Uber Drivers Are Now More Concerned About Charging Than EV Cost
When it comes to convincing millions of drivers to get behind the wheel of electric vehicles, Uber Technologies Inc. has good news and bad news. First, the positive: Prices are coming down to levels at which EV cost is no longer the top issue preventing drivers in the US and UK from going electric. This is a first in the four years Uber has been surveying drivers.
Yahoo
an hour ago
- Yahoo
Oil up, but stocks look to slide after U.S. attacks on Iran
Oil up, but stocks look to slide after U.S. attacks on Iran originally appeared on TheStreet. The U.S. attack on Iranian nuclear facilities on Saturday changes the focus of what's ahead for the U.S. economy in the last full week of June. Because everyone is waiting to see what Iran will do, other than fire missiles on Israel. That's what happened late Saturday. 💵💰💰💵 The three biggest questions a day later: How will energy and stock markets react? Does Iran still have enough enriched uranium to make and deploy a small nuclear weapon? Will Iran move to block the ships from passing from the Persian Gulf through the Strait of Hormuz into global shipping lanes? Outside geopolitics, economic events coming up include Federal Reserve Chairman Jerome Powell's testimony before Congress on Tuesday and an important inflation nuclear question is on the table because U.S. officials weren't sure Sunday if the attacks on facilities at Fordow, Natanz and Isfahan actually destroyed nuclear materials. Vice President J.D. Vance, in fact, suggested that Iran's nuclear stock pile is still intact. If that's the case, it's possible Iran could assemble a first-generation weapon. That would be as powerful as the bombs dropped on Hiroshima and Nagasaki in 1945, Robert Pape of the Chicago Project on Security and Threats told MSNBC's Alex Witt on Sunday. Not having this awful idea become reality depends on cooler heads prevailing. A key issue: If Iran is willing to discuss destroying or otherwise ceding control its nuclear development efforts. The Trump Administration is threatening more attacks if Iran rejects the demand. Blocking the Strait of Hormuz, through which 25% of the world's crude oil passes — headed mostly to China, India and Asia — will send global oil prices surging and, ultimately, will boost gasoline prices in the United States and elsewhere. Stocks and bonds also would slump. Crude oil futures in New York opened up nearly $3 a barrel, then fell back quickly. At 7:30 p.m. EDT, crude was was up $2.12 to $75.99. Brent crude, the global benchmark, jumped to as high as $81.40, then fell back to $79.20 per barrel, up $2.19 Crude oil settled at $73.84 a barrel on Friday, up 34 cents. or 1.2%, from Thursday and up 21.5% so far in June. AAA's daily report on gasoline prices put the U.S. average at $3.218 a gallon, down slightly from Saturday's $3.129. Stock index futures were lower in early trading Sunday with S&P 500 futures off 28 points to 5,990. Futures based on the Dow Jones Industrial Average were down just 184 points to 42,333. Nasdaq-100 futures had fallen 137 points to 21,710. Stocks overall were flat last week even as global tensions heated up. Some defense-oriented stocks slipped on Friday. Palantir Technologies () was off 2% to $137.30. Lockheed Martin () , however, was up 0.4% to $470.56. Federal Reserve Chairman Jerome Powell, who is always verbally battered by President Trump, will testify before the Congress twice this week. The questions almost certainly focus on the Iran situation and its impact on the economy. He will also have to explain why the Fed is so stubborn about NOT cutting its key federal funds rate. The Fed decided last week to leave its federal funds rate at 4.25% to 4.5%. One Fed governor, Christopher Waller, who voted in support of holding rates steady, thinks a rate cut could come in July. Mary Daly, president of the Federal Reserve Bank of San Francisco, thinks the Fed will have better information by September. The federal funds rate mostly affects short-term rates. Bond yields influence rates on, say, home mortgages and auto loans. The 30-year mortgage rate was just under 7% on Friday. Powell's first appearance is before the House Financial Services Committee on Tuesday and the Senate Banking Committee on Wednesday. More Economic Analysis: Federal Reserve prepares strong message on long-term interest rates Massive city workers union approves strike Analyst makes bold call on stocks, bonds, and gold The most important economic report this coming week is the Personal Consumption Expenditures Index (PCE), due Friday from the U.S. Bureau of Economic Analysis. This is the Federal Reserve's preferred inflation rate. The index for May is expected to show a 2.3% year-over-year index. The core index, stripping out food and energy, is expected to rise 2.6%, up slightly from April. The inflation rate is still the lowest since March 2021, Barrons says. Four reports come this week that will help clarify the condition of the housing market. Existing homes sales for May, due Monday from the National Association of Realtors. Most estimates are around 4.1 million units on a seasonally-adjusted annual basis, up From April's 4 million rate. S&P Case-Shiller Home Price Index, due Tuesday from Standard & Poor's. New-home sales, due Wednesday from the Commerce Department. Pending home sales, due Thursday from the National Association of Home Builders. S&P Global reports its flash purchasing manager index reports for June. These measure what manufacturing and services companies are actually buying. The Conference Board comes out with its monthly Consumer Confidence Index report for June Tuesday morning It may show a slight gain because the data were collected as stocks were rallying after April's stock-market slump. The University of Michigan offers its revised Consumer Sentiment Index report on Friday. Its early version suggested consumers were a touch less worried and cited the market up, but stocks look to slide after U.S. attacks on Iran first appeared on TheStreet on Jun 23, 2025 This story was originally reported by TheStreet on Jun 23, 2025, where it first appeared. Sign in to access your portfolio
